Association between Alzheimer's disease and COVID-19: A

bidirectional Mendelian randomization

Di Liu^{1#}, Xiaoyu Zhang^{1#}, Weijie Cao¹, Jie Zhang¹, Manshu Song², Weijia Xing³, Wei Wang^{1,2,3}, Qun Meng¹, Youxin Wang^{1,2}

¹Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, 100069, China;

²School of Medical and Health Sciences, Edith Cowan University, Perth, 60127, Australia

³School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, 271016, Shandong Province, China.

#These authors contributed equally to this study.

Youxin Wang, PhD, Professor

School of Public Health, Capital Medical University

No.10 Xitoutiao, Youanmenwai Street, Fengtai District, Beijing, 100069, China

Tel: +8613581719105; wangy@ccmu.edu.cn

Abstract

Background In observational studies, Alzheimer's disease (AD) has been associated with an increased risk of Coronavirus disease 2019 (COVID-19), and the prognosis of COVID-19 can affect nervous systems. However, the causality between these conditions remains to be determined.

Methods This study sought to investigate the bidirectional causal relations of AD

with COVID-19 using two-sample Mendelian randomization (MR) analysis.

Results We found that genetically predicted AD was significantly associated with higher risk of severe COVID-19 (odds ratio [OR], 3.329; 95% confidence interval [CI], 1.139-9.725; $P=0.028$). It's interesting that genetically predicted severe COVID-19 was also significantly associated with higher risk of AD (OR, 1.004; 95% CI, 1.001-1.007; $P=0.018$). In addition, the two strong genetic variants associated with severe COVID-19 was associated with higher AD risk (OR, 1.018; 95% CI, 1.003-1.034; $P=0.018$). There is no evidence to support that genetically predicted AD was significantly associated with COVID-19 susceptibility, and vice versa. No obvious pleiotropy bias and heterogeneity were observed.

Conclusion Overall, AD may causally affect severe COVID-19, and vice versa, performing bidirectional regulation through independent biological pathways.

Key words Alzheimer's disease; Coronavirus disease 2019; Bidirectional mendelian randomization

Introduction

Coronavirus disease (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-COV2) and represents the causative agent of a potentially fatal disease, rapidly developing into a global pandemic¹. The prognosis of COVID-19 can cause impaired vision, loss of smell, and affect reproductive and nervous systems^{2,3}, that is of great global public health concern. A wide range of studies focused on susceptible populations for COVID-19. In the susceptible population of the elderly, specific risk factors such as dementia have been found to be a risk factor (odds ratio [OR] = 3.50, 95% CI: 1.93 to 6.34) for COVID-19 severity in the UK Biobank (UKB)⁴. However, findings from epidemiological studies are prone to unmeasured confounding, and reverse causation.

Mendelian randomization (MR) has become a popular method by which genetic variants robustly associated with exposures can be used as instrumental variables to infer causality from routinely conducted observational studies⁵. Summary Mendelian randomization (SMR) is an excellent strategy to evaluate the causality using summary statistics from GWAS data⁶. Therefore, we performed bidirectional MR analyses for causal inference between Alzheimer's disease (AD), the main type of dementia, and COVID-19 using summary statistics GWAS results of AD and COVID-19. Understanding the bidirectional relations between AD and COVID-19 is of significant public health importance about disease prevention and management of complications.

Methods

Data sources

Genetic association datasets for COVID-19

The summarized data was obtained from the most recent version of GWAS analyses from the COVID-19 host genetics initiative from UK Biobank individuals, which released on July 1, 2020 (<https://www.covid19hg.org/results/>)⁷. Summarized data on COVID-19 included 3523 patients and 36634 control participants, and summarized data on severe COVID-19 included 536 patients and 329391 control participants. In addition, we performed this analysis with another summarized data from the GWAS of severe COVID-19 with respiratory failure reported by Severe Covid-19 GWAS Group⁸ including 835 patients and 1255 control participants from Italy as well as 775 patients and 950 control participants from Spain for supplementary analysis.

Genetic association datasets for Alzheimer's disease

Summarized data on AD were obtained from the International Genomics of Alzheimer Project with 17008 Alzheimer's disease cases and 37154 controls (<https://www.pasteur-lille.fr>)⁹. All GWAS summary statistic data were based on European ancestry populations.

Instrumental variables for AD and COVID-19

For the bidirectional MR analysis, we first applied forward MR analysis to assess the effect of predisposition to AD on the phenotypes of COVID-19 or severe COVID-19 by using genetic variants robustly associated with AD. Then, we performed reverse MR using genetic variants robustly associated with the phenotypes of COVID-19 or

severe COVID-19 as genetic instruments to investigate their effect on AD.

Single nucleotide polymorphisms (SNPs) that achieved significance ($P < 5 \times 10^{-8}$) for the AD were selected as instrumental variables (IVs). SNPs were chosen as IVs for COVID-19 or severe COVID-19 at a significance threshold ($P < 1 \times 10^{-5}$) from the COVID-19 host genetics initiative, because we didn't filter out SNPs as IVs for COVID-19 or severe COVID-19 at a significance threshold ($P < 5 \times 10^{-8}$). In addition, we chose two SNPs (rs11385942 and rs657152) as IVs for severe COVID-19 based on the GWAS of severe COVID-19 with respiratory failure reported by Severe Covid-19 GWAS Group based on the thresholds for genome-wide significance ($P < 5 \times 10^{-8}$) for supplementary analysis.

We only retained independent variants from each other (Linkage disequilibrium [LD], $r^2 < 0.001$). When we encountered genetic variants in LD, the SNP with the lowest p -value was selected. The LD proxies were defined using 1000 genomes European samples. The same method was applied to filter instrumental variables in reverse MR analysis.

MR analysis

In the main analyses, inverse-variance weighted (IVW) method was used to estimate the overall causal association of AD on COVID-19 and severe COVID-19 susceptibility. We additionally conducted sensitivity analyses using the weighted median, penalised weighted median, and MR-Egger regression to account for potential violations of valid instrumental variable assumptions. The MR-Egger

analysis was performed to evaluate pleiotropy based on the intercept. We conducted heterogeneity test in MR analyses using IVWQ test and a leave one out analysis in which we omitted one genetic variant to investigate the influence of pleiotropic genetic variants. Results are presented as odds ratios with their 95% confidence intervals (95% CIs) of outcomes per genetically predicted increase in each exposure factor. All data analyses were performed by “twosampleMR” package in R (R version 3.6.3, R Core Team, 2017).

In terms of various estimates for different measures, we chose the result of main MR method as following rules:

- (1) If no directional pleiotropy in MR estimates (Q statistic: P value > 0.05 , MR-Egger intercept: P value > 0.05), we reported the results of IVW method.
- (2) If directional pleiotropy was detected (MR-Egger intercept: P value < 0.05) and P value > 0.05 for the Q test, we reported the results of MR-Egger method.
- (3) If directional pleiotropy was detected (MR-Egger intercept: P value < 0.05) and P value < 0.05 for the Q test, we reported the results of weighted median method.

The causal relationships between AD and COVID-19 were delineated into four potential categories, which were observed by bidirectional MR. **Figure 1** provided an overview of the bidirectional MR study to investigate these explanations. If the P value was less than 0.05 only in forward MR, genetic variants determined AD was associated with higher COVID-19 risk (Explanation 1). To robustly test Explanation 2, we performed the reverse MR analysis, evaluating whether COVID-19 affected AD. A P value greater than 0.05 indicated that Explanation 2 was unlikely. There are

bidirectionally causal associations between AD and COVID-19, if both P values were less than 0.05 in forward and reverse MR. We identified the results to evaluate Explanation 3, that is, the finding is based on that the selected SNPs as IVs for forward and reverse MR analysis were not overlapped between AD and COVID-19. If the P value was greater than 0.05 in forward and reverse MR, it was interpreted as Explanation 4.

The annotations of SNPs residing in ± 100 kb of the corresponding genes were obtained from annotation files of the Grch37/hg19. To functionally annotate putative SNPs, we conducted functional enrichment analysis for the identified genes using the functional annotation tool “Metascape”¹⁰ and the R package “clusterProfiler”. Gene symbols corresponding to putative genes ($P < 0.05$) were used as the input of the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes enrichment analysis.

Results

Causal association of AD with COVID-19 via forward MR

In the AD→COVID-19 MR analysis, we used 20 independent SNPs as the instrument for AD. As shown in **Table 1**, IVW estimate showed there was no association between the genetically instrumented AD and COVID-19 risk (OR, 1.211; 95%CI, 0.775-1.895; $P=0.401$), without obvious pleiotropy bias (intercept=-0.006, $P=0.673$) and heterogeneity ($P=0.091$). Of note, there was association of the genetically instrumented AD with severe COVID-19 using 19 SNPs (OR, 3.329; 95% CI,

1.139–9.725, $P=0.028$), without directional pleiotropy (intercept= -0.028 , $P=0.318$) and heterogeneity ($P=0.335$). The association of AD with COVID-19 and severe COVID-19 remained robust in the weighted median and penalised weighted median methods, and leave one out analyses (**Figure S1** and **Figure 2**).

Causal association of COVID-19 with AD via reverse MR

As shown in Table 2, the reverse MR analysis showed no significant association of genetically instrumented COVID-19 with AD using 17-SNP instrument (OR, 0.999; 95% CI, 0.990–1.007; $P=0.756$). The association of COVID-19 with AD was robust in the weighted median and penalised weighted median methods, and leave one out analyses (**Figure S2**). Pleiotropy bias (P for MR-Egger intercept= 0.263) and heterogeneity ($P=0.738$) were also not detected. It is worth mentioning that the genetically instrumented severe COVID-19 was causally associated with AD using 15-SNP instrument (OR, 1.004; 95% CI, 1.001–1.007; $P=0.018$). The causal effect of severe COVID-19 on AD was not robust using weighted median (OR, 1.004; 95% CI, 0.999–1.009; $P=0.117$), penalised weighted median (OR, 1.004; 95% CI, 0.999–1.008; $P=0.112$) and MR-Egger regression (OR, 0.999; 95% CI, 0.989–1.008; $P=0.820$), respectively. There was limited evidence of heterogeneity and horizontal pleiotropy based on the Q test ($P=0.738$) and MR-Egger intercept test ($P=0.263$). In terms of various estimates for different measures, we reported the results of IVW method. The association of severe COVID-19 with AD remained robust in the leave one out analyses (**Figure 3**). In addition, genetically predicted severe COVID-19 was significantly associated with higher risk of AD using the two strong genetic variants

of rs11385942 (locates at 3p21.31) and rs657152 (9q34.2, ABO blood-group) as IVs for severe COVID-19 (OR, 1.018; 95% CI, 1.003-1.034; $P=0.018$).

Functional bioinformatics

The SNPs as IVs for AD were annotated to 126 unique genes (**Table S1**). GO enrichment analysis of biological process, molecular function, and cellular component pathways showed that the identified genes were involved in 20 GO terms (**Figure 4**), such as negative regulation of amyloid precursor protein catabolic process, immunoglobulin mediated immune response, regulation of GTPase activity, cellular oxidant detoxification, regulation of GTPase activity. *APOE*, *ABCA7*, *BIN1*, *SORL1* and *CLU* were involved in the pathway of negative regulation of amyloid precursor protein catabolic process and amyloid beta formation. The SNPs as IVs for severe COVID-19 were annotated to 31 unique genes (**Table S2**). GO enrichment showed that the identified genes were involved in 3 GO terms (**Figure 5**), including regulation of chromosome organization, post-translational protein modification and positive regulation of GTPase activity. *DRD1* and *MCTP1* were involved in the pathway of regulation of neurotransmitter secretion and transport. It is important to note that the shared pathway of the regulation of GTPase activity might link AD and severe COVID-19.

Discussion

To our knowledge, this is the first study to investigate the causal relationship between

AD and severe COVID-19 using a bidirectional MR. Our study showed that AD may causally affect severe COVID-19, and vice versa, performing bidirectional regulation through independent biological pathways.

Our study found that AD was causally associated with the susceptibility of severe COVID-19, but not COVID-19, might indicating that AD patients infected with severe COVID-19 were more likely to be severe phenotype. The finding was consistent with the observational epidemiology study, which found that pre-existing dementia was associated with the risk of COVID-19 hospitalization and death increase⁴. In addition, the study showed that *ApoE*ε4ε4 homozygotes were more likely to be COVID-19 positives (OR = 2.31, 95% CI: 1.65 to 3.24, *P* = 1.19E-6) compared to ε3ε3 homozygotes in the UKBiobank Community Cohort. The *ApoE*ε4ε4 genotype was associated with a 14-fold increase in risk of AD compared to the common ε3ε3 genotype in populations with European ancestries¹¹. Therefore, AD patients with the *ApoE* ε4ε4 allele might increase risks of severe COVID-19 infection¹². In addition, the genes annotated by genetic variants strongly associated with AD were involved in the pathway of immune response. That could explain the death of most severe COVID-19 patients due to the inflammatory storm^{13 14}.

This is the first study to identify the prognosis of COVID-19. We found that severe COVID-19 might cause AD. Notably, the COVID-19 cases endanger the elderly, especially those with cardiovascular illness including diabetes mellitus, hypertension, and coronary heart disease^{15 16}. The increasing MR studies have found that coronary artery disease, higher body mass index, lifetime smoking and

dyslipidemia were causally associated with the susceptibility of COVID-19¹⁷⁻²⁰, which were also risk factors for AD^{21 22}. The reasons underlying AD also may relate to the proinflammatory effect associated with severe COVID-19. An exaggerated inflammatory response appears a major driver of immunopathology in SARS-CoV-2 infected patients²³, with benefits of targeting the acute inflammatory response in severe COVID-19 cases²⁴. It has been reported that bi-directional communication existed between the central nervous system and the peripheral immune system²⁵. Activated peripheral immune cells that enter the brain through the blood brain barrier (BBB) may modulate the pathogenesis of AD^{26 27}. The genes *DRD1* and *MCTP1* annotated by genetic variants strongly associated with severe COVID-19 were involved in the pathway of regulation of neurotransmitter secretion and transport. SARS-COV2 might be a causative factor involved in the infectious etiology of AD. In addition, ABO blood type might play an important role in the development of COVID-19 and AD^{8 28}. Taken together, the findings indicated that subjects infected with severe COVID-19 with respiratory failure might be of higher risk of AD after survival of COVID-19.

No overlapped genetic variants as IVs for AD and severe COVID-19 was overserved, indicating that AD and severe COVID-19 might be bidirectionally regulated by different pathogenic pathways. The shared pathway of the regulation of GTPase activity might underly the association between AD and severe COVID-19²⁹⁻³¹, which needed further investigation to get more data support and further experimental study to verify.

The bidirectional MR analysis aims to explore positive and negative feedback loops resulting in regulation of the COVID -19 as a causal or a downstream effect on diseases. We should notice some limitations. First of all, stratified analyses or analyses adjusted for other covariates were not possible on the account of using available summary statistics datasets. The GWAS of Severe COVID-19 with respiratory failure and the COVID-19 host genetics initiative from UK Biobank individuals include small sample size, which may lead to small effect for the MR estimate and limit the IVs for COVID-19 for reverse MR analysis. The annotated genes by genetic variants were only a preliminary exploration of the possible mechanisms, and gene expression quantitative trait loci analysis need to be validated in the future studies. Last, our findings are based on European cohort make it difficult to represent the universal conclusions for other ethnic groups.

In conclusion, our study showed that AD may causally affect severe COVID-19, which were of clinical significance for particular attention to individuals with AD during this pandemic. Conversely, severe COVID-19 may induce AD, indicating that the future study should pay attention to the prognosis of COVID-19.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Disclosure of Potential Conflicts of Interest

All authors have approved the manuscript and its submission. No potential conflicts

of interest were disclosed by the authors.

Funding/Support

The study was supported by grants from the National Key R&D Program of China (2017YFE0118800)—European Commission Horizon 2020 (779238-PRODEMOS), the National Natural Science Foundation of China (81872682 and 81773527), and the China-Australian Collaborative Grant (NSFC 81561128020-NHMRC APP1112767). Di Liu was supported by China Scholarship Council (CSC 201908110339).

Role of the Funder/Sponsor

The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *The Lancet Infectious diseases* 2020;20(5):533-34. doi: 10.1016/s1473-3099(20)30120-1 [published Online First: 2020/02/23]
2. Palmer K, Monaco A, Kivipelto M, et al. The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing. *Aging clinical and experimental research* 2020;32(7):1189-94. doi: 10.1007/s40520-020-01601-4 [published Online First: 2020/05/28]
3. Fotuhi M, Mian A, Meysami S, et al. Neurobiology of COVID-19. *J Alzheimers Dis* 2020 doi: 10.3233/jad-200581 [published Online First: 2020/06/17]
4. Atkins JL, Masoli JAH, Delgado J, et al. Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. *The journals of gerontology Series A, Biological sciences and medical sciences* 2020 doi: 10.1093/gerona/glaa183 [published Online First: 2020/07/21]
5. Sekula P, Del Greco MF, Pattaro C, et al. Mendelian Randomization as an Approach to Assess Causality Using Observational Data. *Journal of the American Society of Nephrology : JASN* 2016;27(11):3253-65. doi: 10.1681/asn.2016010098 [published Online First: 2016/11/02]
6. Dimou NL, Tsilidis KK. A Primer in Mendelian Randomization Methodology with a Focus on Utilizing Published Summary Association Data. *Methods Mol Biol* 2018;1793:211-30. doi: 10.1007/978-1-4939-7868-7_13 [published Online First: 2018/06/08]
7. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *European journal of human genetics : EJHG* 2020;28(6):715-18. doi: 10.1038/s41431-020-0636-6 [published Online First: 2020/05/15]
8. Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med* 2020 doi: 10.1056/NEJMoa2020283 [published Online First: 2020/06/20]
9. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature genetics* 2013;45(12):1452-8. doi: 10.1038/ng.2802 [published Online First: 2013/10/29]
10. Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat Commun* 2019;10(1):1523. doi: 10.1038/s41467-019-09234-6 [published Online First: 2019/04/05]
11. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *Jama* 1997;278(16):1349-56. [published Online First: 1997/10/29]
12. Kuo CL, Pilling LC, Atkins JL, et al. ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants. *Aging* 2020;12(12):12222-33. doi: 10.18632/aging.103405 [published Online First: 2020/06/09]
13. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. *Journal of medical virology* 2020 doi: 10.1002/jmv.26232 [published Online First: 2020/06/28]
14. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science*

- 2020;368(6490):473-74. doi: 10.1126/science.abb8925 [published Online First: 2020/04/19]
15. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine* 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032 [published Online First: 2020/02/29]
16. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395(10229):1054-62. doi: 10.1016/s0140-6736(20)30566-3 [published Online First: 2020/03/15]
17. Zhang K, Guo Y, Wang Z-X, et al. Causally Associations of Blood Lipids Levels with COVID-19 Risk: Mendelian Randomization Study. *medRxiv* 2020:2020.07.07.20147926. doi: 10.1101/2020.07.07.20147926
18. Mark PJ, Gkatzionis A, Walker V, et al. Cardiometabolic traits, sepsis and severe covid-19 with respiratory failure: a Mendelian randomization investigation. *medRxiv* 2020:2020.06.18.20134676. doi: 10.1101/2020.06.18.20134676
19. Freuer D, Linseisen J, Meisinger C. Obesity has an impact on COVID-19 susceptibility and severity: a two-sample Mendelian randomization study. *medRxiv* 2020:2020.07.14.20153825. doi: 10.1101/2020.07.14.20153825
20. Wu L, Zhu J, Wu C. Mendelian randomization analysis to characterize causal association between coronary artery disease and COVID-19. *medRxiv* 2020:2020.05.29.20117309. doi: 10.1101/2020.05.29.20117309
21. Broce IJ, Tan CH, Fan CC, et al. Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. *Acta Neuropathol* 2019;137(2):209-26. doi: 10.1007/s00401-018-1928-6 [published Online First: 2018/11/11]
22. Reitz C. Dyslipidemia and the risk of Alzheimer's disease. *Current atherosclerosis reports* 2013;15(3):307. doi: 10.1007/s11883-012-0307-3 [published Online First: 2013/01/19]
23. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory medicine* 2020;8(4):420-22. doi: 10.1016/s2213-2600(20)30076-x [published Online First: 2020/02/23]
24. Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Science immunology* 2020;5(48) doi: 10.1126/sciimmunol.abd0110 [published Online First: 2020/06/07]
25. Holmes C, Butchart J. Systemic inflammation and Alzheimer's disease. *Biochemical Society transactions* 2011;39(4):898-901. doi: 10.1042/bst0390898 [published Online First: 2011/07/27]
26. Quan N, Banks WA. Brain-immune communication pathways. *Brain, behavior, and immunity* 2007;21(6):727-35. doi: 10.1016/j.bbi.2007.05.005 [published Online First: 2007/07/03]
27. Takeda S, Sato N, Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. *Frontiers in aging neuroscience* 2014;6:171. doi: 10.3389/fnagi.2014.00171 [published Online First: 2014/08/15]
28. De Marco M, Venneri A. 'O' blood type is associated with larger grey-matter volumes in the cerebellum. *Brain Res Bull* 2015;116:1-6. doi: 10.1016/j.brainresbull.2015.05.005 [published Online First: 2015/05/26]
29. Aguilar BJ, Zhu Y, Lu Q. Rho GTPases as therapeutic targets in Alzheimer's disease. *Alzheimer's research & therapy* 2017;9(1):97. doi: 10.1186/s13195-017-0320-4 [published Online First:

2017/12/17]

30. Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. *Embo j* 2020;39(10):e105114. doi: 10.15252/embj.20105114 [published Online First: 2020/04/05]
31. Brufsky A, Marti JLG, Nasrazadani A, et al. Boning up: amino-bisphosphonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. *J Transl Med* 2020;18(1):261. doi: 10.1186/s12967-020-02433-6 [published Online First: 2020/07/01]

Table 1 Causal association of AD with COVID-19 via forward MR

Phenotype	IVs for AD (SNPs)	OR (95% CI)	Beta (SE)	<i>P</i>
COVID vs. Lab/self-reported negative				
IVW	20	1.211 (0.775-1.895)	0.192 (0.228)	0.401
Weighted median	20	1.145 (0.697-1.880)	0.135 (0.253)	0.593
Penalised weighted median	20	1.136 (0.704-1.831)	0.127 (0.244)	0.601
MR_Egger	20	1.340 (0.699-2.569)	0.293 (0.332)	0.389
β (intercept)	-	-	-0.006 (0.014)	0.673
Q statistic	-	-	-	0.091
Severe respiratory confirmed COVID vs. population				
IVW	19	3.329 (1.139-9.725)	1.203 (0.547)	0.028
Weighted median	19	4.691 (1.282-17.165)	1.546 (0.662)	0.019
Penalised weighted median	19	4.874 (1.353-17.558)	1.584 (0.654)	0.015
MR_Egger	19	5.405 (1.314-22.238)	1.687 (0.722)	0.032
β (intercept)	-	-	-0.028 (0.027)	0.318
Q statistic	-	-	-	0.335

Beta is the estimated effect size.

AD: Alzheimer's disease; CI: confidence intervals; IVs: instrumental variables; IVW, inverse-variance weighted; MR mendelian randomization; OR: odds ratio; SE, standard error; SNP, single-nucleotide polymorphism.

Table 2 Causal association of COVID-19 with AD via reverse MR

Phenotype	IVs for COVID (SNPs)	OR (95% CI)	Beta (SE)	<i>P</i>
COVID vs. Lab/self-reported negative				
IVW	17	0.999 (0.990-1.007)	-0.0013 (0.0043)	0.756
Weighted median	17	1.0003 (0.989-1.011)	0.0002 (0.0056)	0.960
Penalised weighted median	17	1.0006 (0.989-1.011)	0.0006 (0.0055)	0.919
MR_Egger	17	1.0015 (0.977-1.026)	0.0015 (0.0123)	0.905
β (intercept)	-	-	-0.0007 (0.0028)	0.891
Q statistic	-	-	-	0.421
Severe respiratory confirmed COVID vs. population				
IVW	15	1.004 (1.0007-1.007)	0.0042 (0.0018)	0.018
Weighted median	15	1.004 (0.999-1.009)	0.0038 (0.0024)	0.117
Penalised weighted median	15	1.004 (0.999-1.008)	0.0038 (0.0024)	0.112
MR_Egger	15	0.999 (0.989-1.008)	-0.0011 (0.0049)	0.820
β (intercept)	-	-	0.0025 (0.0021)	0.263
Q statistic	-	-	-	0.738
Severe respiratory confirmed COVID vs. population*				
IVW	2	1.018 (1.003-1.034)	0.018 (0.008)	0.018

*The two SNPs (rs11385942 and rs657152) were selected as IVs for severe COVID-19 based on the GWAS of severe COVID-19 with respiratory failure reported by Severe Covid-19 GWAS Group based on thresholds for genome-wide significance ($P < 5 \times 10^{-8}$).

Beta is the estimated effect size.

AD: Alzheimer's disease; CI: confidence intervals; IVs: instrumental variables; IVW, inverse-variance weighted; MR mendelian randomization; OR: odds ratio; SE, standard error; SNP, single-nucleotide polymorphism

Figure legends

Figure. 1 Analysis pipeline to evaluate the explanations for the observed associations between AD and COVID-19

AD: Alzheimer's disease; COVID-19: Coronavirus disease 2019; GWAS: genome-wide association study; MR: mendelian randomization; SNP, single-nucleotide polymorphism

Figure. 2 Leave-one-out analysis: each row represents a MR analysis of AD on severe COVID-19 using all instruments except for the SNP listed on the y-axis. The point represents the odds ratio with that SNP removed and the line represents 95% confidence interval.

AD: Alzheimer's disease; COVID-19: Coronavirus disease 2019; MR: mendelian randomization; SNP, single-nucleotide polymorphism

Figure. 3 Leave-one-out analysis: each row represents a MR analysis of severe COVID-19 on AD using all instruments except for the SNP listed on the y-axis. The point represents the odds ratio with that SNP removed and the line represents 95% confidence interval.

AD: Alzheimer's disease; COVID-19: Coronavirus disease 2019; MR: mendelian randomization; SNP, single-nucleotide polymorphism

Figure. 4 Functional enrichment analysis of the genes annotated by SNPs as IVs for

AD. A) Enriched GO terms via the genes; B) The association between genes and the enriched GO clusters

AD: Alzheimer's disease; IVs: instrumental variables; GO, gene ontology; SNP, single-nucleotide polymorphism

Figure. 5 Functional enrichment analysis of the genes annotated by SNPs as IVs for severe COVID-19. A) Enriched GO terms via the genes; B) The association between genes and the enriched GO clusters

COVID-19: Coronavirus disease 2019; IVs: instrumental variables; GO, gene ontology; SNP, single-nucleotide polymorphism

Figure. S1 Leave-one-out analysis: each row represents a MR analysis of AD on COVID-19 using all instruments except for the SNP listed on the y-axis. The point represents the odds ratio with that SNP removed and the line represents 95% confidence interval.

AD: Alzheimer's disease; COVID-19: Coronavirus disease 2019; MR: mendelian randomization; SNP, single-nucleotide polymorphism

Figure. S2 Leave-one-out analysis: each row represents a MR analysis of COVID-19 on AD using all instruments except for the SNP listed on the y-axis. The point represents the odds ratio with that SNP removed and the line represents 95% confidence interval.

AD: Alzheimer's disease; COVID-19: Coronavirus disease 2019; MR: mendelian

randomization; SNP, single-nucleotide polymorphism

MR leave-one-out sensitivity analysis for COVID - 19 on AD